BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33414907)

  • 1. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
    Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
    Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
    Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
    Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
    Okano N; Matsuki R; Toki M; Gondo K; Ochiai K; Watanabe S; Tateishi H; Kogure M; Suzuki Y; Sugiyama M; Nagashima F; Shibahara J; Sakamoto Y; Furuse J
    Intern Med; 2023 Feb; 62(3):327-334. PubMed ID: 35793961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial).
    Okada KI; Kimura K; Yamashita YI; Shibuya K; Matsumoto I; Satoi S; Yoshida K; Kodera Y; Akahori T; Hirono S; Eguchi H; Asakuma M; Tani M; Hatano E; Ikoma H; Ohira G; Hayashi H; Wan K; Shimokawa T; Kawai M; Yamaue H;
    Ann Gastroenterol Surg; 2023 Nov; 7(6):997-1008. PubMed ID: 37927936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
    Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M;
    Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer.
    Tajima H; Ohta T; Okazaki M; Yamaguchi T; Ohbatake Y; Okamoto K; Nakanuma S; Kinoshita J; Makino I; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Nakamura H
    Mol Clin Oncol; 2019 Aug; 11(2):157-166. PubMed ID: 31281650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
    Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
    Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.
    Murokawa T; Okabayashi T; Sui K; Tabuchi M; Iwata J
    Surg Case Rep; 2022 Feb; 8(1):29. PubMed ID: 35171354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis.
    Damm M; Efremov L; Birnbach B; Terrero G; Kleeff J; Mikolajczyk R; Rosendahl J; Michl P; Krug S
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement.
    Ikenaga N; Miyasaka Y; Ohtsuka T; Nakata K; Adachi T; Eguchi S; Nishihara K; Inomata M; Kurahara H; Hisaka T; Baba H; Nagano H; Ueki T; Noshiro H; Tokunaga S; Ishigami K; Nakamura M;
    Ann Surg Oncol; 2023 Jan; 30(1):193-202. PubMed ID: 36207481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.
    Tajima H; Kitagawa H; Tsukada T; Nakanuma S; Okamoto K; Sakai S; Makino I; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Itoh H; Takamura H; Ninomiya I; Fushida S; Fujimura T; Ohta T
    Mol Clin Oncol; 2013 Jul; 1(4):768-772. PubMed ID: 24649244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
    Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
    Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
    Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
    Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.
    Tajima H; Ohta T; Kitagawa H; Okamoto K; Sakai S; Makino I; Kinoshita J; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Fushida S; Tani T; Fujimura T; Ikeda H; Kitamura S
    Exp Ther Med; 2012 May; 3(5):787-792. PubMed ID: 22969969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.
    Bauer TM; Patel MR; Forero-Torres A; George TJ; Assad A; Du Y; Hurwitz H
    Onco Targets Ther; 2018; 11():2399-2407. PubMed ID: 29750040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.
    Murakami M; Fujimori N; Ohno A; Matsumoto K; Teramatsu K; Takamatsu Y; Takeno A; Oono T; Abe T; Ideno N; Ikenaga N; Nakata K; Nakamura M; Ishigami K; Ogawa Y
    Discov Oncol; 2022 Jan; 13(1):2. PubMed ID: 35201490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.